Vir Biotechnology reported the first positive result in a new late-stage program for its once-monthly hepatitis D therapy tobevibart. The company said 44% of patients receiving tobevibart achieved the study’s target endpoint, a key milestone in a field where treatment options have been limited. The update intensifies competitive pressure for other hepatitis D-focused developers, including Gilead and Mirum Pharmaceuticals, which are also advancing combination or next-line strategies. For investors and pharma teams, the headline signal is both efficacy and the move from earlier-stage concepts into pivotal evidence. Regulatory and payer relevance will hinge on durability, safety signals (including immune-related issues), and how the trial’s population compares with prior datasets for response rates and viral suppression kinetics. Additional phase data will likely determine whether tobevibart shifts the treatment algorithm.